New Hep C Treatment Being Tested
REHOVOT, Israel - U.S. health officials estimate that more Americans will die during this decade of hepatitis C (HCV) infection than AIDS.
Officials at XTL Biopharmaceuticals Ltd. are trying to make a difference in these statistics. After successfully passing Phase IA clinical trails earlier this year with their drug XTL-002, researchers have announced the commencement of a Phase IB clinic study. The drug is a fully human, high-affinity monoclonal antibody that has reduced the viral levels of HCV virus.
The World Health Organization (WHO) estimates some 170 million people worldwide suffer from chronic HCV. There are 4 million carriers of the virus in the United States alone.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
